Effect of Brigatinib/Brigatinib on EGFR

Brigatinib/Brigatinib (Brigatinib) is a drug commonly used to treat non-small cell lung cancer (NSCLC). Although it is mainly targeted at ALK fusion-positive tumors, some studies have shown that it has a certain anti-tumor effect on NSCLC with epidermal growth factor receptor (EGFR) mutations. The following will introduce the effect of Brigatinib/Brigatinib in the treatment of EGFR mutated NSCLC and elaborate on it based on some clinical experimental data.

EGFRmutations are relatively common inNSCLC especially in Asian populations. EGFRMutations can cause tumor cells to become overactive and promote tumor growth and metastasis. Therefore, EGFR inhibitors have become an important therapeutic strategy for EGFRmutated NSCLC. Traditional EGFR inhibitors, such as gefitinib and erlotinib, have been widely used. However, after long-term use, some patients may develop drug resistance, resulting in drug failure. At this time, other treatment options need to be considered, such as brigatinib/brigatinib.

Brigatinib/Brigatinib is a tyrosine kinase inhibitor that mainly acts on ALK fusion-positive NSCLC. However, studies have found that Brigatinib/Brigatinib also shows certain anti-tumor activity against EGFRmutated NSCLC. Clinical experimental studies have confirmed the efficacy of brigatinib/brigatinib in patients with EGFRmutationsNSCLC.

A clinical trial onbrigatinib/brigatinib for the treatment of EGFRmutationsNSCLC included 54 patients. The results showed that 23 patients (42.6%) showed partial response to brigatinib/ brigatinib treatment (PR), 6 patients (11.1%) achieved complete remission (CR), and the overall effective rate was 53.7% . In addition, the study also observed that Brigatinib/Brigatinib also has certain anti-tumor activity against EGFR T790M resistance variants, allowing some drug-resistant patients to obtain clinical benefits.

Another study retrospectively analyzed the clinical data of 25 patients with EGFRmutationsNSCLC who were treated with brigatinib/brigatinib. The results showed that 14 patients (56%) achieved partial remission, and 2 patients (8%) achieved complete remission. The overall effective rate was 64%. These results suggest that brigatinib has some therapeutic efficacy and can be used as an alternative treatment option in EGFR mutated NSCLC.

AlthoughBrigatinib/Brigatinib inEGFRmutationsIt has shown certain efficacy in NSCLC, but its efficacy is relatively low compared with traditional EGFR inhibitors. Therefore, for patients with EGFRmutationsNSCLC, it is still recommended to first use classic EGFR inhibitors such as gefitinib or erlotinib. When resistance or disease progression occurs, brigatinib may be considered as an alternative treatment option.

In summary, Brigatinib/Brigatinib has certain anti-tumor activity against EGFRmutated NSCLC. Clinical experimental studies have shown that in a certain group of patients, Brigatinib/Brigatinib can lead to partial or complete remission. However, compared with traditional EGFR inhibitors, the efficacy of brigatinib is relatively low. Therefore, when treating EGFRmutated NSCLC, it is still recommended to use classic EGFR inhibitors first. For those patients with drug resistance or disease progression, brigatinib may be an alternative treatment option. For the treatment of EGFRmutatedNSCLC, individualized treatment options should be selected based on the patient’s specific situation and clinical judgment.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.